Yuanyuan Ding1, Lin Qiu2, Qian Xu1, Lixue Song1, Sufang Yang3, Tao Yang4. 1. Department of Pharmacy, General Hospital of Beijing Military Area East-City District, East Four-Tenth Street, Beijing 100029, China. 2. Department of Stomatology, General Hospital of Beijing Military Area East-City District, East Four-Tenth Street, Beijing 100029, China. 3. Ambulant Clinic, Department of General Political, People's Liberation Army Beijing 100011, China. 4. Department of Oral and Maxillofacial Surgery, General Hospital of Shenyang Military Area Shenyang 110016, China.
Abstract
OBJECTIVE: To evaluate the relationship between the subtype of cells/cellular constituents (the density of T lymphocyte subsets, B lymphocyte, macrophages, and FOXP3 positive cells in 93 patients with meningioma, WHO grades I and II) in the tumor microenvironment and clinicopathological parameters (gender, age, tumor location, size, recurrence and pathological type) of meningioma. METHODS: Immunohistochemical demonstrations of CD20 and CD4 lymphocytes, CD68, and FOXP3 expression were performed. In order to assess the densities of CD4, CD20, CD68 and FOXP3 positive cells in 93 meningioma patients, the results were derived from independent reviews by two pathologists. Chi-square test was used for independent samples. RESULTS: There were no relationships between the CD4(+), CD68(+) cell subsets and patients' age, sex, tumor size, grade and the recurrence of tumor. However, patients with recurrence had a significantly higher density of CD20(+) B cells compared to patients with no recurrence (P = 0.003). For the Foxp3(+) cell subset, results showed us that more female patients had high density of Foxp3(+) cells compared with male patients, while the opposite results were observed in the low density group (P = 0.009). Furthermore, the density of Foxp3(+) cells was significantly correlated with the tumor size (P = 0.004) and the pathological types (P = 0.004). CONCLUSION: Results in this study demonstrate that higher CD20(+) B cell density in the tumor is associated with lower tumor recurrence and the density of Foxp3(+) cells is significantly correlated with the patients' sex, tumor size and the pathological types. The results also suggest that understanding of the cellular constituents of tumors and the tumor microenvironment may help investigate the tumor pathogenesis and immunotherapies in meningioma.
OBJECTIVE: To evaluate the relationship between the subtype of cells/cellular constituents (the density of T lymphocyte subsets, B lymphocyte, macrophages, and FOXP3 positive cells in 93 patients with meningioma, WHO grades I and II) in the tumor microenvironment and clinicopathological parameters (gender, age, tumor location, size, recurrence and pathological type) of meningioma. METHODS: Immunohistochemical demonstrations of CD20 and CD4 lymphocytes, CD68, and FOXP3 expression were performed. In order to assess the densities of CD4, CD20, CD68 and FOXP3 positive cells in 93 meningiomapatients, the results were derived from independent reviews by two pathologists. Chi-square test was used for independent samples. RESULTS: There were no relationships between the CD4(+), CD68(+) cell subsets and patients' age, sex, tumor size, grade and the recurrence of tumor. However, patients with recurrence had a significantly higher density of CD20(+) B cells compared to patients with no recurrence (P = 0.003). For the Foxp3(+) cell subset, results showed us that more female patients had high density of Foxp3(+) cells compared with male patients, while the opposite results were observed in the low density group (P = 0.009). Furthermore, the density of Foxp3(+) cells was significantly correlated with the tumor size (P = 0.004) and the pathological types (P = 0.004). CONCLUSION: Results in this study demonstrate that higher CD20(+) B cell density in the tumor is associated with lower tumor recurrence and the density of Foxp3(+) cells is significantly correlated with the patients' sex, tumor size and the pathological types. The results also suggest that understanding of the cellular constituents of tumors and the tumor microenvironment may help investigate the tumor pathogenesis and immunotherapies in meningioma.
Authors: Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531
Authors: Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422
Authors: John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes Journal: Cancer Immunol Immunother Date: 2020-07-13 Impact factor: 6.968
Authors: Yuping D Li; Dorina Veliceasa; Jason B Lamano; Jonathan B Lamano; Gurvinder Kaur; Dauren Biyashev; Craig M Horbinski; Tim J Kruser; Orin Bloch Journal: Cancer Immunol Immunother Date: 2019-04-27 Impact factor: 6.968